Brain Tumours

Conclusions In order to make progress in pHGG, DIPG or aHGG Biologically targeted therapies are needed Biomarkers are required for patient selection Accurate preclinical models needed Extrapolation of data/ studies only possible for Shared targets and defined molecular groups Needs to be confirmed if these targets are relevant in different tumour entities e.g. DIPG > pHGG > aHGG